Cargando…
Methylene Blue Is a Nonspecific Protein–Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19
We have previously identified methylene blue, a tricyclic phenothiazine dye approved for clinical use for the treatment of methemoglobinemia and for other medical applications as a small-molecule inhibitor of the protein–protein interaction (PPI) between the spike protein of the SARS-CoV-2 coronavir...
Autores principales: | Chuang, Sung-Ting, Papp, Henrietta, Kuczmog, Anett, Eells, Rebecca, Condor Capcha, Jose M., Shehadeh, Lina A., Jakab, Ferenc, Buchwald, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144480/ https://www.ncbi.nlm.nih.gov/pubmed/35631447 http://dx.doi.org/10.3390/ph15050621 |
Ejemplares similares
-
Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
por: Barsi, Szilvia, et al.
Publicado: (2022) -
Development of a novel, entirely herbal-based mouthwash effective against common oral bacteria and SARS-CoV-2
por: Bencze, Bálint, et al.
Publicado: (2023) -
The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue
por: Konrat, Robert, et al.
Publicado: (2022) -
Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein-Protein Interaction–a Mechanism that can Contribute to its Antiviral Activity Against COVID-19
por: Bojadzic, Damir, et al.
Publicado: (2021) -
Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations
por: Dabholkar, Neha, et al.
Publicado: (2021)